Literature DB >> 28882594

Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3.

Paul D Wright1, Emma L Veale2, David McCoull3, David C Tickle3, Jonathan M Large3, Emma Ococks3, Gemma Gothard3, Catherine Kettleborough3, Alistair Mathie2, Jeffrey Jerman3.   

Abstract

Two-pore domain potassium channels (K2Ps) are characterized by their four transmembrane domain and two-pore topology. They carry background (or leak) potassium current in a variety of cell types. Despite a number of important roles there is currently a lack of pharmacological tools with which to further probe K2P function. We have developed a cell-based thallium flux assay, using baculovirus delivered TASK3 (TWIK-related acid-sensitive K+ channel 3, KCNK9, K2P9.1) with the aim of identifying novel, selective TASK3 activators. After screening a library of 1000 compounds, including drug-like and FDA approved molecules, we identified Terbinafine as an activator of TASK3. In a thallium flux assay a pEC50 of 6.2 ( ±0.12) was observed. When Terbinafine was screened against TASK2, TREK2, THIK1, TWIK1 and TRESK no activation was observed in thallium flux assays. Several analogues of Terbinafine were also purchased and structure activity relationships examined. To confirm Terbinafine's activation of TASK3 whole cell patch clamp electrophysiology was carried out and clear potentiation observed in both the wild type channel and the pathophysiological, Birk-Barel syndrome associated, G236R TASK3 mutant. No activity at TASK1 was observed in electrophysiology studies. In conclusion, we have identified the first selective activator of the two-pore domain potassium channel TASK3.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activator; K2P; KCNK9; TASK3; Terbinafine

Mesh:

Substances:

Year:  2017        PMID: 28882594     DOI: 10.1016/j.bbrc.2017.09.002

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  TASK-3: New Target for Pain-Relief.

Authors:  Wen-Jing Ren; Henning Ulrich; Alexey Semyanov; Peter Illes; Yong Tang
Journal:  Neurosci Bull       Date:  2020-05-26       Impact factor: 5.203

2.  A "Target Class" Screen to Identify Activators of Two-Pore Domain Potassium (K2P) Channels.

Authors:  David McCoull; Emma Ococks; Jonathan M Large; David C Tickle; Alistair Mathie; Jeffrey Jerman; Paul D Wright
Journal:  SLAS Discov       Date:  2020-12-29       Impact factor: 3.341

Review 3.  Development of Non-opioid Analgesics Targeting Two-pore Domain Potassium Channels.

Authors:  Lu Huang; Guangyin Xu; Ruotian Jiang; Yuncheng Luo; Yunxia Zuo; Jin Liu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

Review 4.  Targeting Mitochondrial Ion Channels to Fight Cancer.

Authors:  Magdalena Bachmann; Roberto Costa; Roberta Peruzzo; Elena Prosdocimi; Vanessa Checchetto; Luigi Leanza
Journal:  Int J Mol Sci       Date:  2018-07-15       Impact factor: 5.923

5.  Modulation of TASK-1/3 channels at the hypoglossal motoneuron pool and effects on tongue motor output and responses to excitatory inputs in vivo: implications for strategies for obstructive sleep apnea pharmacotherapy.

Authors:  Patrick Gurges; Hattie Liu; Richard L Horner
Journal:  Sleep       Date:  2021-01-21       Impact factor: 5.849

Review 6.  Structural Insights into the Mechanisms and Pharmacology of K2P Potassium Channels.

Authors:  Andrew M Natale; Parker E Deal; Daniel L Minor
Journal:  J Mol Biol       Date:  2021-04-20       Impact factor: 5.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.